ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly COVID-19 Antibodies by Quarter
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%)
Eli Lilly COVID-19 Antibodies: -100.0% in Q4 2023, down 4.0 pts from a year earlier. That is the lowest of the 9 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
“|| COVID-19 antibodies (d) | — | 38.0 | (100)% | — | 2,023.5 | (100)%”
Source: Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | -100.0% | -4.0 pts | Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗ |
| Q3 2023 | Sep 30, 2023 | -100.0% | -178.0 pts | Form 10-Q FY2023Q3 (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | -100.0% | -87.0 pts | Form 10-Q FY2023Q2 (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | -100.0% | -181.0 pts | Form 10-Q FY2023Q1 (filed 2023-04-27) ↗ |
| Q4 2022 | Dec 31, 2022 | -96.0% | -118.0 pts | Earnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗ |
| Q3 2022 | Sep 30, 2022 | 78.0% | – | Form 10-Q FY2022Q3 (filed 2022-11-01) ↗ |
| Q2 2022 | Jun 30, 2022 | -13.0% | – | Form 10-Q FY2022Q2 (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 81.0% | – | Form 10-Q FY2022Q1 (filed 2022-04-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 22.0% | – | Earnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗ |
Cite this data
StockData. (2026). Eli Lilly COVID-19 Antibodies (%), quarterly Q4 2021–Q4 2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-covid19antibodies-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.